<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="32850">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02679001</url>
  </required_header>
  <id_info>
    <org_study_id>ML29933</org_study_id>
    <nct_id>NCT02679001</nct_id>
  </id_info>
  <brief_title>A Comparative Study to Observe the Effect of Concomitant Use of Corticosteroid Treatment in Rheumatoid Arthritis (RA) Participants Who Are Treated With a Tumor Necrosis Factor (TNF) Inhibitor or Tocilizumab (TCZ) as Their Second Biological Treatment.</brief_title>
  <official_title>A COMPARATIVE OBSERVATIONAL STUDY FOLLOWING THE USE OF CONCOMITANT CORTICOSTEROID TREATMENT IN RA PATIENTS WHO ARE TREATED WITH A TNF INHIBITOR OR TOCILIZUMAB AS THEIR SECOND BIOLOGICAL TREATMENT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This six months non-interventional, observational, post-marketing, multi-center and local
      study will evaluate the differences in the use of corticosteroids between RA participants
      receiving TCZ or a TNF-inhibitor, in participants who have discontinued the use of a
      TNF-inhibitor as their first biological treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants with a decrease in dose of oral corticosteroids during the study</measure>
    <time_frame>From baseline to 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants achieving C59CDAI remission (&lt;/=2.8)</measure>
    <time_frame>From baseline to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants achieving CDAI LDA (&lt;/=10)</measure>
    <time_frame>From baseline to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants using non-biologic disease-modifying anti-rheumatic drugs (C58MARDs) at treatment initiation and at the end of observation period</measure>
    <time_frame>Baseline, Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants for whom non-biologic DMARDs was added during observation period</measure>
    <time_frame>From baseline to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with dose change in biological treatment during study</measure>
    <time_frame>From baseline to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with use of oral corticosteroids at treatment initiation and at end of study</measure>
    <time_frame>From baseline to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants who started or stopped oral corticosteroid treatment during the study period</measure>
    <time_frame>From baseline to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with increased/decreased/stable dose of corticosteroids from baseline to end of study</measure>
    <time_frame>From baseline to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with change in dose of corticosteroids during study but with same dose at study end as at baseline</measure>
    <time_frame>From baseline to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulated doses of oral corticosteroids during study period</measure>
    <time_frame>From baseline to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of corticosteroids including but not limited to intra-articular, intravenously, inhaled, topical and/or intramuscular/subcutaneous injections</measure>
    <time_frame>From baseline to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulated doses of corticosteroids including but not limited to intra-articular, intravenously, inhaled, topical and/or intramuscular/subcutaneous injections</measure>
    <time_frame>From baseline to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulated doses of all corticosteroids during study period</measure>
    <time_frame>From baseline to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean dose of corticosteroids at start and end of study</measure>
    <time_frame>From baseline to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline to end of study of corticosteroids</measure>
    <time_frame>Baseline, Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline to end of study in DAS28 (sedimentation rate [SR]) score</measure>
    <time_frame>Baseline, Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline to end of study in DAS28 (C-Reactive Protein [CRP]) score</measure>
    <time_frame>Baseline, Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline to end of study in crohns disease activity index (CDAI) score</measure>
    <time_frame>Baseline, Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline to end of study in swollen 28 joint count</measure>
    <time_frame>Baseline, Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline to end of study in tender 28 joint count</measure>
    <time_frame>Baseline, Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline to end of study in Physician Global Assessment of disease activity (Visual Analogue Scale [VAS] scale)</measure>
    <time_frame>Baseline, Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline to end of study in Patient Global Assessment of disease activity (VAS scale)</measure>
    <time_frame>Baseline, Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline to end of study in Health Assessment Questionnaire Disability Index (HAQ-DI)</measure>
    <time_frame>Baseline, Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline to end of study in Severity of pain (VAS scale)</measure>
    <time_frame>Baseline, Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline to end of study in EULAR response</measure>
    <time_frame>Baseline, Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants achieving DAS28 remission (less than or equal to [&lt;/=] 2.6)</measure>
    <time_frame>From baseline to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants achieving DAS 28 Low Disease Activity (LDA) (&lt;/=3.2)</measure>
    <time_frame>From baseline to 6 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>RA participants treated with a TNF inhibitor or TCZ</arm_group_label>
    <description>Participants with RA receiving TNF-inhibitor or TCZ according to standard of care and in line with the current summary of product characteristics (SPC)/local labeling will be observed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TNF inhibitor/TCZ</intervention_name>
    <description>Participants with RA receiving TNF-inhibitor or TCZ according to standard of care and in line with the current SPC/local labeling will be observed.</description>
    <arm_group_label>RA participants treated with a TNF inhibitor or TCZ</arm_group_label>
    <other_name>COTTON</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Participants with a diagnosis of moderate to severe RA according to the revised (1987) ACR
        criteria or 2010 ACR/EULAR RA classification criteria who have had an insufficient
        response or intolerance to their first TNF-inhibitor.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 18 years of age.

          -  With a diagnosis of moderate to severe RA according to the revised (1987) American
             College of Rheumatology (ACR) criteria or 2010 ACR/ European League Against
             Rheumatism (EULAR) RA classification criteria.

          -  Have had an insufficient response or intolerance to their first TNF-inhibitor
             (including biosimilars for TNF-inhibitors).

          -  The treating physician has made the decision to commence TCZ or TNF-inhibitor
             treatment. Participants need to have a Disease Activity Score (DAS) 28 assessment at
             initiation of their second biological treatment.

          -  Have been given oral and written information about the study and have no objection to
             the data concerning him/her being subject to computerized data processing, have given
             informed consent.

        Exclusion Criteria:

          -  Have had more than one TNF-inhibitor prior to the enrolment visit.

          -  Have had biological treatment other than TNF-inhibitors.

          -  Participants that are continuously treated with per oral corticosteroids for any
             other indication than RA (at baseline).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: ML29933 www.roche.com/about_roche/roche_worldwide.htm</last_name>
    <phone>888-662-6728 (U.S. and Canada)</phone>
    <email>global.rochegenentechtrials@roche.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Arvika</city>
        <zip>671 80</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Huddinge</city>
        <zip>SE-141 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Karlskrona</city>
        <zip>37185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Malmo</city>
        <zip>205 02</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Malm√∂</city>
        <zip>21138</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Oerebro</city>
        <zip>70185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Skoevde</city>
        <zip>54185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Stockholm</city>
        <zip>18288</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Trelleborg</city>
        <zip>231 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Uppsala</city>
        <zip>75185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>September 1, 2016</lastchanged_date>
  <firstreceived_date>February 8, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
